Result of AGM

Rhea-AI Summary

MaxCyte, a leader in cell-engineering, announced that all resolutions at its Annual General Meeting on October 29, 2021, were passed, except for Proposal 2 concerning the 2021 Equity Incentive Plan. The company focuses on advancing cell-based research and next-generation cell therapies through its proprietary Flow Electroporation® platform, which supports the expansive cell therapy market. MaxCyte's ExPERT™ platform includes a range of instruments and software aimed at facilitating the development of innovative cell-based medicines.

Positive

• All resolutions passed at the Annual General Meeting, boosting shareholder confidence.
• MaxCyte's proprietary Flow Electroporation® platform supports innovative cell-based research and therapies, positioning the company favorably in a growing market.
• The ExPERT™ platform is well-developed with multiple instruments and robust intellectual property, enhancing MaxCyte's competitive edge.

Negative

• Proposal 2 regarding the 2021 Equity Incentive Plan was not approved, which may raise concerns about employee retention and incentive structures.

GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that at its Annual General Meeting held on 29^th October 2021, all resolutions were duly passed, with the exception of Proposal 2, relating to the approval of the 2021 Equity Incentive Plan.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400  ir@maxcyte.com
US Media Relations Laura Morgan Sam Brown Healthcare Communications	+1 951-333-9110 lauramorgan@sambrown.com
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

FAQ

What happened at MaxCyte's Annual General Meeting on October 29, 2021?

All resolutions were passed except for Proposal 2 related to the 2021 Equity Incentive Plan.

What does MaxCyte focus on in its business operations?

MaxCyte is focused on cell-engineering and providing technologies for cell-based research and therapies.

What is the significance of the Flow Electroporation® platform for MaxCyte?

The Flow Electroporation® platform supports the development and commercialization of innovative cell-based medicines.

What is included in MaxCyte's ExPERT™ platform?

The ExPERT™ platform includes various instruments and software designed for the high-growth cell therapy market.

How might the rejection of Proposal 2 affect MaxCyte investors?

The rejection of Proposal 2 could impact employee motivation and retention, potentially affecting company performance.